Skip to content

A randomized controlled trial for the effects of the water-soluble tomato extract for the hypercholesterolemia populations

A randomized controlled trial for the effects of Fruitflow (the water-soluble tomato extract) for the hypercholesterolemia populations

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800015904
Enrollment
Unknown
Registered
2018-04-27
Start date
2018-05-07
Completion date
Unknown
Last updated
2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypercholesterolemia

Interventions

2:the water-soluble tomato extract

Sponsors

Peking University Third Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. People with high serum cholesterol (TC is greater than 5.2 and <7.2mmol/L, and/or LDL-C is greater than 3.4 and <4.9mmol/L.); 2. aged 35-65 years; 3. and have had dyslipidemia for the first time and not taken antilipemic, or who have had dyslipidemia and taken lipid regulating agents, but stopped taking lipid regulating agents for more than 3 months.

Exclusion criteria

Exclusion criteria: 1. blood pressure = 160/100mmHg; 2. Low platelet count (whole blood <100 x 10^9/L); 3. the prothrombin time (PT) was outside the normal reference range; 4. in the past three months, aspirin, aspirin-containing drugs, other drugs that can alter platelet or coagulation system function, etc.; 5. the fish oil and evening primrose oil supplements were taken within the last month; 6. regular consumption of tomatoes, tomato sauce/juice (=5 days per week); 7. severe functional disorder or organic diseases of the heart, liver or kidney; 8. pregnant or lactating women; 9. Abnormal menstrual cycle, taking birth control pills or hormone replacement therapy; or menopausal syndrome women; 10. persons who are not suitable for venous blood collection; 11. allergies to tomato and its ingredients; 12. Known history of HIV or active HCV/HBV infection or any uncontrolled active systemic infection; 13. Currently participating or having participated in another clinical trial in the three previous months; 14. Unable to carry out functional tests and questionnaires correctly.

Design outcomes

Primary

MeasureTime frame
Platelet functions;

Countries

China

Contacts

Public ContactCHANG CUIQING

Peking University Third Hospital

13521960678@163.com+86 13521960678

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026